In the medical product pavilion, an area recording one of the highest traffic at the ongoing 7th China International Import Expo in Shanghai, multinational companies are showcasing the latest innovative technologies and solutions at the platform that connects stakeholders from home and abroad.

Johnson & Johnson announced at its booth the China market launch of INVEGA HAFYERA, a medicine for the treatment of schizophrenia in adults. Making its China debut at the CIIE in 2022, the therapy is the first and sole long-acting injection that needs to be taken only twice a year.

"We're proud to present groundbreaking products here at the CIIE. We hope such advanced medical technologies can benefit from CIIE's influence to be introduced to the China market at an accelerated pace to better serve our patients. Also, we look forward to promoting local innovations from China to the world," said Edward Zhou, president of Johnson & Johnson MedTech China.

Pfizer's inflammation and immunology business unit is showcasing breakthrough dermatology solutions at the CIIE. Pfizer features innovative therapies, including Cibinqo and Staquis, providing patients with comprehensive treatment options for mild, moderate, and severe atopic dermatitis (AD).

AD is a common immuno-inflammatory disease seriously affecting health and quality of life of millions of people in the country. The disease is characterized by chronic and recurrent itching and skin injuries.

GSK announced during the CIIE that its innovative drug Bepirovirsen is in Phase III clinical studies, and has been granted breakthrough therapy designation by China's Center for Drug Evaluation. As the first therapy with "functional cure" as the endpoint of the trial, studies so far have shown its great potential in the treatment of chronic hepatitis B, said the company.

China still faces challenges of hepatitis B prevention and control due to its large population base, although the infection rate has declined in recent years, according to experts.

Showcasing its innovative therapy to treat systemic lupus erythematosus (SLE), an autoimmune disease, GSK also announced at the CIIE to kick off a public welfare project that supports SLE patients and various parties involved, aiming to jointly help improve diagnosis and treatment level in the disease field, and improve the living environment of patients.